Figure 3. Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and TCS, Patients With Coexisting ASD
Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and TCS by Time Point, Patients With Coexisting ASD at Baseline
Format
PNG
Source
Zynerba Pharmaceuticals, Inc.